Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gerald T. Proehl
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Beta
- 0.69
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -23.59
Financials
Net Income
$-2.97MEBITDA
$-2.97MFree Cash Flow
$-2.53MEPS (diluted)
$-0.74Shares Outstanding (diluted)
4.02M+115811.9%Operating Expenses
$641.5KCash & Debt
$4.41MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-7.56M | $-8.16 |
| 2024 | $0.00 | $-12.29M | $-80.32 |
| 2023 | $0.00 | $-7.79M | $-401.80 |
| 2022 | $0.00 | $-9.61M | $-2088.00 |
| 2021 | $0.00 | $-7.90M | $-152.70 |
| 2020 | $0.00 | $-3.24M | $-932.64 |
| 2019 | $0.00 | $-4.72M | $-95.50 |
Valuation
DRMAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsaccessnewswire.com·42d ago·Neutral
… can purchase a one-month kit or subscribe for convenient recurring delivery - SAN DIEGO, CA / ACCESS Newswire / August 25, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company's Tome skincare brand. The Foundational Treatment is now available for immediate purchase at www.tomeski…
View source ↗ - Newsaccessnewswire.com·46d ago·Neutral
…- Tome Foundational Treatment is a once-weekly topical mask for skin renewal - SAN DIEGO, CA / ACCESS Newswire / August 21, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected to start shipping on August 25, 2026.
View source ↗ - Newsaccessnewswire.com·55d ago·Neutral
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 - Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 - - Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand - SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatol
View source ↗
Earnings
Wed, Nov 18(in 6 weeks)
Consensus estimate $-0.55 per share
Typical surprise +1.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.74 vs $-0.55miss
- Wed, May 13$-0.48 vs $-0.53beat
- Thu, Mar 26$-1.52 vs $-1.54beat
- Fri, Nov 14$-1.65 vs $-1.59miss
- Wed, Aug 13$-1.66 vs $-2.90beat
- Wed, May 14$-4.50 vs $-4.50beat
Estimates and results for DRMA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DRMA officers and directors.
- Bought
- $1k
- Sold
- $13
1 trade
1 trade
- Scott Kathleen D.sold
- Bedoya-toro Munera Maria Ebought
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DRMA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.